Pfizer is returning to its position as a stable pharmaceutical leader after several weak years. The second quarter of 2025 provided compelling evidence that its strategy of focusing on efficiency, improving operating margins and developing next-generation medicines is starting to work. The company increased both sales and earnings, while reaffirming full-year revenue guidance and raising its adjusted earnings per share estimate. This indicates management's growing confidence in its ability to restore growth and stable cash flow after a challenging period of declining demand for its covid products.

In addition to strong financial results, Pfizer $PFEmade significant progress in research and development. The company is expanding its portfolio of innovative therapies, from oncology to cardiovascular drugs to vaccines. Savings programs, which are expected to deliver more than $7 billion in net savings by 2027, are on track and contributing to operating margin growth. The company is…